23 March 2018
EMA/PDCO/187894/2018
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 20-23 March 2018

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

20 March 2018, 17:30- 19:00, room 3A

21 March 2018, 08:30- 19:00, room 3A

22 March 2018, 08:30- 19:00, room 3A

23 March 2018, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions 7

1.1. Welcome and declarations of interest of members, alternates and experts 7

1.2. Adoption of agenda 7

1.3. Adoption of the minutes 7

2. Opinions 8

2.1. Opinions on Products 8

2.1.1. Palonosetron / fosnetupitant - EMEA-001198-PIP03-17 8

2.1.2. Irbesartan / Amlodipine - EMEA-002192-PIP02-17 8

2.1.3. (2R)-2-Amino-1-[3-({2-[p-(4-{3-[(3,5-diamino-6-chloro-2-pyrazinyl)carbonyl]guanidino}butyl)phenoxy]ethyl}{3-[(2R)-2-amino-6-guanidinohexanoylamino]propyl}amino)propylamino]-6-guanidino-1-hexanone hexahydrochloride - EMEA-002291-PIP01-17 8

2.1.4. Ranibizumab - EMEA-000527-PIP05-17 9

2.1.5. Clostridium botulinum neurotoxin type A - EMEA-001039-PIP03-17 9

2.1.6. Ibuprofen / paracetamol - EMEA-002002-PIP02-17 10

2.1.7. Eszopiclone - EMEA-002309-PIP01-17 10

2.1.8. Tenofovir Alafenamide / Emtricitabine - EMEA-001577-PIP03-17 10

2.2. Opinions on Compliance Check 11

2.2.1. Drospirenone - EMEA-C-001495-PIP01-13-M01 11

2.2.2. Pibrentasvir / Glecaprevir - EMEA-C1-001832-PIP01-15 11

2.2.3. Abatacept - EMEA-C-000118-PIP02-10-M03 11

2.2.4. Lanadelumab - EMEA-C2-001864-PIP01-15-M02 11

2.2.5. Dabigatran etexilate mesilate - EMEA-C3-000081-PIP01-07-M10 12

2.2.6. Ibrutinib - EMEA-C2-001397-PIP03-14-M03 12

2.2.7. Omadacycline - EMEA-C1-000560-PIP02-15 12

2.2.8. Omadacycline - EMEA-C1-000560-PIP03-15 13

2.2.9. Ivacaftor - EMEA-C8-000335-PIP01-08-M12 13

2.2.10. Esketamine hydrochloride - EMEA-C1-001428-PIP03-15 13

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan 14

2.3.1. Angiotensin II - EMEA-001912-PIP02-16-M01 14

2.3.2. Treprostinil - EMEA-000207-PIP01-08-M06 14

2.3.3. Edoxaban (tosylate) - EMEA-000788-PIP02-11-M07 14

2.3.4. Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit), Paullinia cupana Kunth, Theobroma cacao L. - EMEA-001835-PIP01-15-M03 15

2.3.5. Testosterone - EMEA-001529-PIP02-14-M01 15

2.3.6. Guselkumab - EMEA-001523-PIP02-14-M02 15

2.3.7. Peginterferon alfa-2a - EMEA-000298-PIP01-08-M06 16
2.3.8. Galcanezumab - EMEA-001860-PIP03-16-M01 16
2.3.9. Inebilizumab - Orphan - EMEA-001911-PIP01-15-M01 17
2.3.10. Sunitinib malate - EMEA-000342-PIP01-08-M07 17
2.3.11. Naloxone (hydrochloride) - EMEA-001567-PIP01-13-M03 17
2.4. Opinions on Re-examinations 18
2.5. Finalisation and adoption of opinions 18

3. Discussion of applications 18

3.1. Discussions on Products D90-D60-D30 18
3.1.1. Empagliflozin - EMEA-000828-PIP04-16-M01 18
3.1.2. Lasmiditan - EMEA-002166-PIP01-17 18
3.1.3. Setmelanotide - Orphan - EMEA-002209-PIP01-17 18
3.1.4. Anetumab ravtansine - Orphan - EMEA-002123-PIP01-17 18
3.1.5. Daratumumab - Orphan - EMEA-002152-PIP01-17 19
3.1.6. Isatuximab - Orphan - EMEA-002205-PIP01-17 19
3.1.7. Etripamil - EMEA-002303-PIP01-17 19
3.1.8. EMEA-002312-PIP01-17 19
3.1.9. EMEA-001710-PIP04-17 19
3.1.10. Cenicriviroc - EMEA-001999-PIP02-17 19
3.1.11. Fluticasone propionate - Orphan - EMEA-002289-PIP01-17 20
3.1.12. Hepcidin-25 acetate - Orphan - EMEA-002083-PIP01-16 20
3.1.13. Human monoclonal IgG1 antibody against Tissue Factor Pathway Inhibitor - Orphan - EMEA-002285-PIP01-17 20
3.1.14. Voclosporin - EMEA-002264-PIP01-17 20
3.1.15. Upadacitinib Hemihydrate - EMEA-001741-PIP04-17 20
3.1.16. Brincidofovir - Orphan - EMEA-001904-PIP02-17 20
3.1.17. Evobrutinib - EMEA-002284-PIP01-17 21
3.1.18. Sarizotan Hydrochloride - Orphan - EMEA-001808-PIP03-17 21
3.1.19. Immunoglobulin G4 - EMEA-002290-PIP01-17 21
3.1.20. Diphtheria Toxin Interleukin-3 Fusion Protein - Orphan - EMEA-002244-PIP01-17 21
3.1.21. Molgramostim - Orphan - EMEA-002282-PIP01-17 21
3.1.22. Mavacamten - EMEA-002231-PIP01-17 21
3.1.23. Trandolapril / verapamil - EMEA-002276-PIP01-17 22
3.1.24. Somapacitan - EMEA-001469-PIP02-17 22
3.1.25. Relamorelin - EMEA-002323-PIP01-17 22
3.1.26. Brincidofovir - Orphan - EMEA-001904-PIP03-18 22
3.1.27. Ibalizumab - EMEA-002311-PIP01-17 22
3.1.28. Pretomanid - Orphan - EMEA-002115-PIP01-17 22

3.1.29. Rezafungin acetate - EMEA-002319-PIP01-17 23
3.1.30. Tedizolid phosphate - EMEA-001379-PIP03-17 23
3.1.31. Andecaliximab - EMEA-002304-PIP01-17 23
3.1.32. Brigatinib - EMEA-002296-PIP01-17 23
3.1.33. Botulinum Toxin Type A - EMEA-002149-PIP02-17 23
3.1.34. Palovarotene - EMEA-001662-PIP03-17 23
3.1.35. Meloxicam / Bupivacaine - EMEA-002246-PIP01-17 24
3.2. Discussions on Compliance Check 24
3.2.1. Cobicistat / Darunavir - EMEA-C2-001280-PIP01-12-M01 24
3.2.2. Ozanimod - EMEA-C3-001710-PIP02-14-M02 24
3.2.3. Conestat Alfa - EMEA-C-000367-PIP01-08-M07 24
3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan 24
3.3.1. Apixaban - EMEA-000183-PIP01-08-M06 24
3.3.2. Apixaban - EMEA-000183-PIP02-12-M02 25
3.3.3. Betrixaban - EMEA-001834-PIP02-16-M01 25
3.3.4. Apremilast - EMEA-000715-PIP03-11-M05 25
3.3.5. Dupilumab - EMEA-001501-PIP01-13-M05 25
3.3.6. Vestronidase alfa - Orphan - EMEA-001540-PIP01-13-M03 25
3.3.7. Human Fibrinogen - EMEA-001208-PIP01-11-M04 25
3.3.8. Baricitinib - EMEA-001220-PIP01-11-M03 26
3.3.9. Emapalumab - Orphan - EMEA-002031-PIP01-16-M01 26
3.3.10. Ceftaroline fosamil - EMEA-000769-PIP01-09-M08 26
3.3.11. Ceftazidime / avibactam - EMEA-001313-PIP01-12-M07 26
3.3.12. Dasabuvir sodium monohydrate - EMEA-001439-PIP01-13-M02 26
3.3.13. EMEA-001975-PIP01-16-M01 26
3.3.14. Lamivudine (3TC) / Dolutegravir (DTG) - EMEA-001940-PIP01-16-M01 27
3.3.15. Ritonavir / paritaprevir / ombitasvir - EMEA-001440-PIP01-13-M02 27
3.3.16. Sofosbuvir - EMEA-001276-PIP01-12-M02 27
3.3.17. Tenofovir Alafenamide / Emtricitabine - EMEA-001577-PIP02-14-M03 27
3.3.18. Velpatasvir / Sofosbuvir - EMEA-001646-PIP01-14-M02 27
3.3.19. Fenfluramine hydrochloride - Orphan - EMEA-001990-PIP01-16-M01 28
3.3.20. Perampanel - EMEA-000467-PIP01-08-M09 28
3.3.21. Spheroids of human autologous matrix-associated chondrocytes - EMEA-001264-PIP01-12-M02 28
3.3.22. Formoterol fumarate dihydrate / Beclometasone dipropionate - EMEA-000548-PIP01-09-M08 28
3.3.23. Peanut flour - EMEA-001734-PIP01-14-M02 28
3.3.24. Lurasidone hydrochloride - EMEA-001230-PIP01-11-M04 29
3.3.25. Etelcalcetide - EMEA-001554-PIP01-13-M02 29

4. Nominations 29
4.1. List of letters of intent received for submission of applications with start of procedure 29 May 2018 for Nomination of Rapporteur and Peer reviewer 29
4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver. 29
4.3. Nominations for other activities 29
5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction 29
6. Discussion on the applicability of class waivers 29
6.1. Discussions on the applicability of class waiver for products..... 30
6.1.1. Recombinant human monoclonal antibody to GM-CSF - EMEA-02-2018 30
6.1.2. Inhibitor of ADAMTS-5 - EMEA-03-2018 30
7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver 30
7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver 30
8. Annual reports on deferrals 30
9. Organisational, regulatory and methodological matters 30
9.1. Mandate and organisation of the PDCO..... 30
9.1.1. Change to timing of Scientific Committee Chair and Vice-Chair elections 30
9.2. Coordination with EMA Scientific Committees or CMDh-v 31
9.2.1. Committee for Medicinal Products for Human Use (CHMP)..... 31
9.2.2. Committee for Medicinal Products for Human Use (CHMP)..... 31
9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 31
9.3.1. Non-clinical Working Group: D30 Products identified 31
9.3.2. Formulation Working Group 31
9.3.3. Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) 31
9.3.4. Modelling and Simulation Working Group (MSWG) 32
9.4. Cooperation within the EU regulatory network..... 32
9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)..... 32
9.4.2. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) 32
9.5. Cooperation with International Regulators..... 32
9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee 32
9.7. PDCO work plan..... 32
9.8. Planning and reporting 33
9.8.1. Strategic Review and Learning Meeting (SRLM) to be held in Vienna on 26-28 September 2018..... 33

10. Any other business 33
10.1. AOB topic 33
10.1.1. Reflections and action plan following the Multi-stakeholder workshop to further improve the implementation of the paediatric regulation (held on Tuesday 20 March 2018) 33
10.1.2. Involvement of young people at PDCO 33
11. Breakout sessions 34
11.1.1. Paediatric oncology 34
11.1.2. Neonatology 34
11.1.3. Inventory 34
12. List of participants 35
13. Explanatory notes 38

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted.

1.3. Adoption of the minutes

The minutes of the February 2018 PDCO were adopted and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Palonosetron / fosnetupitant - EMEA-001198-PIP03-17

Helsinn Birex Pharmaceuticals Limited; Prevention of Chemotherapy-Induced Nausea and Vomiting

Day 120 opinion

Other

Summary of committee discussion:

The committee discussed the applicant' clarifications and considered them agreeable. The PDCO re-discussed and endorsed its views expressed on day 90.
Based on the assessment of this application the PDCO adopted a positive opinion on the PIP for palonosetron / fosnetupitant in the condition of Prevention of Chemotherapy-Induced Nausea and Vomiting.

2.1.2. Irbesartan / Amlodipine - EMEA-002192-PIP02-17

WIN MEDICA S.A.; Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine and irbesartan taken as two single-component formulations

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver.
The PDCO recommends granting a waiver for amlodipine / irbesartan for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of hypertension.

2.1.3. (2R)-2-Amino-1-[3-({2-[p-(4-{3-[(3,5-diamino-6-chloro-2-pyrazinyl)carbonyl]guanidino}butyl)phenoxy]ethyl}{3-[(2R)-2-amino-6-guanidinohexanoylamino]propyl}amino)propylamino]-6-guanidino-1-hexanone hexahydrochloride - EMEA-002291-PIP01-17

Shire Pharmaceuticals Ireland Limited; Treatment of dry eye disease

Day 60 opinion

Ophthalmology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for (2R)-2-Amino-1-[3-({2-[p-(4-{3-[(3,5-diamino-6-chloro-2-pyrazinyl)carbonyl]guanidino}butyl)phenoxy]ethyl}{3-[(2R)-2-amino-6-guanidinohexanoylamino]propyl}amino)propylamino]-6-guanidino-1-hexanone hexahydrochloride for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of dry eye disease.

A positive opinion was adopted on D60.

2.1.4. Ranibizumab - EMEA-000527-PIP05-17

Novartis Europharm Limited; Diabetic retinopathy (DR)

Day 60 opinion

Ophthalmology

Summary of committee discussion:

The PDCO re-discussed and endorsed its views expressed on day 30, taking into account the applicant's additional information.
Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Ranibizumab for all subsets of the paediatric population (0 to 18 years of age) in the condition of diabetic retinopathy on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2.1.5. Clostridium botulinum neurotoxin type A - EMEA-001039-PIP03-17

Merz Pharmaceuticals GmbH; Treatment of hemifacial spasm

Day 60 opinion

Ophthalmology / Neurology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Clostridium botulinum neurotoxin type A for all subsets of the paediatric population (0 to less than 18 years of age) in the condition of treatment of hemifacial spasm.
A positive opinion was adopted on D60.

2.1.6. Ibuprofen / paracetamol - EMEA-002002-PIP02-17

Farmalíder, S.A.; R52, R50.9 / Fever, Pain

Day 60 opinion

Pain

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for all subsets of the paediatric population.
The PDCO emphasises that the granting of a waiver for a condition should not prevent the applicant from considering development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.7. Eszopiclone - EMEA-002309-PIP01-17

Alfred E. Tiefenbacher (GmbH & Co. KG); F51.0

Day 60 opinion

Psychiatry

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for all subsets of the paediatric population.
The PDCO emphasises that the granting of a waiver for a condition should not prevent the applicant from considering development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.8. Tenofovir Alafenamide / Emtricitabine - EMEA-001577-PIP03-17

Gilead Sciences International Ltd.; Prevention of human immunodeficiency virus (HIV-1) infection / In combination with safer sex practices for prevention of HIV-1 infection in adolescents aged 12 years and above

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

PDCO granted a positive opinion on the paediatric plan proposed by the applicant.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Drospirenone - EMEA-C-001495-PIP01-13-M01

LABORATIORIOS LEÓN FARMA, S.A.; Prevention of pregnancy

Day 30 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO discussed the compliance request on D30 and a positive opinion was adopted.

2.2.2. Pibrentasvir / Glecaprevir - EMEA-C1-001832-PIP01-15

AbbVie Ltd; Treatment of chronic hepatitis C

Day 30 letter

Infectious Diseases

Summary of committee discussion:

The PDCO discussed the initiated studies and considered that these have been initiated in compliance with the latest Agency's Decision (P/0152/2016) of 14 June 2016.
The PDCO finalised on 23 March 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be initiated until this date.

2.2.3. Abatacept - EMEA-C-000118-PIP02-10-M03

Bristol-Myers Squibb Pharma EEIG; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

Day 30 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO took note of preceding procedures and reports on partially completed compliance (EMEA-C1-000118-PIP02-10-M01).
The PDCO adopted on 23 March 2018 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0099/2018) of 15 March 2018.

2.2.4. Lanadelumab - EMEA-C2-001864-PIP01-15-M02

Shire Pharmaceuticals Ireland Limited; Treatment of hereditary angioedema

Day 30 letter

Other

Summary of committee discussion:

The PDCO discussed the completed PIP studies and considered that these are compliant with the latest Agency's Decision (P/0055/2018) of 09 March 2018.
The PDCO finalised on 23 March 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.5. Dabigatran etexilate mesilate - EMEA-C3-000081-PIP01-07-M10

Boehringer Ingelheim International GmbH; Treatment of thromboembolic events

Day 60 letter

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

Clarification was provided by the applicant on 9 March 2018 PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision (P/0301/2017) of 06 October 2017. In addition PDCO confirmed that Study has been initiated in line with the latest Agency's Decision (P/0301/2017) of 06 October 2017.
The PDCO finalised on 23 March 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be initiated and/or completed until this date.

2.2.6. Ibrutinib - EMEA-C2-001397-PIP03-14-M03

Janssen-Cilag International N.V.; Treatment of mature B-cell neoplasm

Day 60 letter

Oncology

Summary of committee discussion:

The PDCO re-discussed the completed study taking also into account the clarifications provided by the applicant after the D30 discussion and considered that this was compliant with the latest Agency's Decision (P/0398/2017) of 19 December 2017.
The PDCO finalised on 23 March 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.7. Omadacycline - EMEA-C1-000560-PIP02-15

Paratek UK Limited; Treatment of acute bacterial skin and skin structure infections (ABSSSI)

Day 30 letter

Infectious Diseases

Summary of committee discussion:

The PDCO discussed the initiation of study and considered that it is compliant with the latest Agency's Decision (P/0169/2017) of 03 July 2017.
The PDCO finalised on 23 March 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.8. Omadacycline - EMEA-C1-000560-PIP03-15

Paratek UK Limited; Treatment of bacterial pneumonia

Day 30 letter

Infectious Diseases

Summary of committee discussion:

The PDCO discussed the initiation of study and considered that it is compliant with the latest Agency's Decision (P/0168/2017) of 03 July 2017.
The PDCO finalised on 23 March 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.9. Ivacaftor - EMEA-C8-000335-PIP01-08-M12

Vertex Pharmaceuticals (Europe) Limited; Treatment of cystic fibrosis

Day 30 letter

Other

Summary of committee discussion:

The PDCO finalised on 23 March 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.10. Esketamine hydrochloride - EMEA-C1-001428-PIP03-15

Janssen-Cilag International NV; Treatment of Major Depressive Disorder

Day 30 letter

Psychiatry

Summary of committee discussion:

The PDCO noted the assessors' conclusion and confirmed compliance of the studies submitted for check (partial compliance).

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Angiotensin II - EMEA-001912-PIP02-16-M01

La Jolla Pharmaceutical II B.V.; Hypotension associated with distributive or vasodilatory shock

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

All issues having been resolved, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Treprostinil - EMEA-000207-PIP01-08-M06

Ferrer Internacional, S.A.; Primary pulmonary hypertension, Other secondary hypertension / Treatment of pulmonary arterial hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Additional information was provided by the applicant on 8 March 2018.

In conclusion, the PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0059/2015 of 1 April 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Edoxaban (tosylate) - EMEA-000788-PIP02-11-M07

Daiichi Sankyo Europe GmbH; Prevention of arterial thromboembolism, Prevention of venous thromboembolism, Treatment of venous thromboembolism / Prevention of arterial thromboembolism in paediatric cardiac patients at risk of thrombotic events, Acute treatment & secondary prevention of symptomatic recurrent venous thrombotic events (VTE) in paediatric patients at risk

Day 60 opinion

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

Between Day 30 and Day 60 the applicant submitted information as requested. The

PDCO agreed with the requested modification.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0322/2017 of 31/10/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit), Paullinia cupana Kunth, Theobroma cacao L. - EMEA-001835-PIP01-15-M03

LEGACY HEALTHCARE; Treatment of alopecia

Day 60 opinion

Dermatology

Summary of committee discussion:

The PDCO discussed the applicant's clarifications and considered them agreeable. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0364/2016 of 20 December 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Testosterone - EMEA-001529-PIP02-14-M01

Acerus Biopharma Inc.; Male hypogonadism

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

A response to the Day 30 PDCO discussion was provided by the applicant on 06 March 2018.
The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0045/2017 of 17 February 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Guselkumab - EMEA-001523-PIP02-14-M02

Janssen Cilag International NV; Treatment of psoriasis / Treatment of severe plaque psoriasis in children ≥6 to <18 years of age who cannot be adequately controlled with topical agents and/or phototherapy

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO discussed this procedure in D60.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0300/2017 of 4 October 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Peginterferon alfa-2a - EMEA-000298-PIP01-08-M06

Roche Registration Ltd; Treatment of Chronic Hepatitis C in combination with other agent(s) / Treatment of chronic hepatitis B

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 30 discussion.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0010/2016 of 29/01/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Galcanezumab - EMEA-001860-PIP03-16-M01

Eli Lilly and Company Limited; Prevention of migraine headaches

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0341/2016 of 5 December 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion

2.3.9. Inebilizumab - Orphan - EMEA-001911-PIP01-15-M01

MedImmune, LLC ; Neuromyelitis optica (NMO) or NMO spectrum disorders (NMOSD)

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0344/2016 of 2 December 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. Sunitinib malate - EMEA-000342-PIP01-08-M07

Pfizer Limited; CD10 code C49.4 malignant neoplasms of connective and soft tissue of abdomen - gastro-intestinal stromal tumours (GIST) / Treatment of gastro-intestinal stromal tumour in paediatric patients aged 6 to less than 18

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0263/2017 of 4 September 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Naloxone (hydrochloride) - EMEA-001567-PIP01-13-M03

Develco Pharma GmbH; Treatment of opioid-induced constipation

Day 60 opinion

Other / Pain / Gastroenterology-Hepatology

Summary of committee discussion:

At Day 60 the PDCO agreed with most of the requested changes.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0075/2016 of 18/03/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

None

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Empagliflozin - EMEA-000828-PIP04-16-M01

Treatment of type 1 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.2. Lasmiditan - EMEA-002166-PIP01-17

Migraine with and without aura

Day 90 discussion

Neurology

3.1.3. Setmelanotide - Orphan - EMEA-002209-PIP01-17

Rhythm Pharmaceuticals, Inc; Treatment of appetite and general nutrition disorders / Treatment of obesity and/or hyperphagia associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway

Day 90 discussion

Nutrition

3.1.4. Anetumab ravtansine - Orphan - EMEA-002123-PIP01-17

Bayer AG; Treatment of acute myeloid leukaemia, Treatment of mesothelioma / , Treatment of patients from 6 months to less than 18 years of age with relapsed and/or refractory mesothelin-positive acute myeloid leukaemia

Day 90 discussion

Oncology

3.1.5. Daratumumab - Orphan - EMEA-002152-PIP01-17

Janssen-Cilag international N.V.; Lymphoid malignancies except mature B-cell neoplasms / Daratumumab in combination with standard chemotherapy is indicated for the treatment of paediatric patients from birth to 18 years with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Day 90 discussion

Oncology

3.1.6. Isatuximab - Orphan - EMEA-002205-PIP01-17

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue / Treatment of relapsed, refractory acute lymphoblastic leukemia in combination with standard treatment in paediatric patients with no more than one prior salvage therapy, Treatment of relapsed, refractory acute myeloblastic leukemia in combination with standard treatment in paediatric patients with no more than one prior salvage therapy

Day 90 discussion

Oncology

3.1.7. Etripamil - EMEA-002303-PIP01-17

Treatment of acute paroxysmal supraventricular tachycardia (PSVT)

Day 60 discussion

Cardiovascular Diseases

3.1.8. EMEA-002312-PIP01-17

Treatment of moderate to severe atopic dermatitis inadequately responsive to topical therapies or where topical treatments are not appropriate

Day 60 discussion

Dermatology

3.1.9. EMEA-001710-PIP04-17

Treatment of Crohn's disease

Day 60 discussion

Gastroenterology-Hepatology

3.1.10. Cenicriviroc - EMEA-001999-PIP02-17

NASH with Stage 2-3 fibrosis

Day 60 discussion

Gastroenterology-Hepatology

3.1.11. Fluticasone propionate - Orphan - EMEA-002289-PIP01-17

Adare Pharmaceuticals; eosinophilic esophagitis

Day 60 discussion

Gastroenterology-Hepatology

3.1.12. Hepcidin-25 acetate - Orphan - EMEA-002083-PIP01-16

La Jolla Pharmaceutical II B.V.; Treatment of iron overload

Day 60 discussion

Haematology-Hemostaseology

3.1.13. Human monoclonal IgG1 antibody against Tissue Factor Pathway Inhibitor - Orphan - EMEA-002285-PIP01-17

Pfizer Limited; Treatment of coagulation disorders congenital

Day 60 discussion

Haematology-Hemostaseology

3.1.14. Voclosporin - EMEA-002264-PIP01-17

Treatment of Systemic Lupus Erythematosus / Treatment of Active Lupus Nephritis

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.15. Upadacitinib Hemihydrate - EMEA-001741-PIP04-17

Treatment of Atopic Dermatitis

Day 60 discussion

Immunology-Rheumatology-Transplantation / Dermatology

3.1.16. Brincidofovir - Orphan - EMEA-001904-PIP02-17

Chimerix UK Limited; Treatment of AdV in immunocompromised patients

Day 60 discussion

Infectious Diseases

3.1.17. Evobrutinib - EMEA-002284-PIP01-17

Treatment of multiple sclerosis

Day 60 discussion

Neurology

3.1.18. Sarizotan Hydrochloride - Orphan - EMEA-001808-PIP03-17

Newron Pharmaceuticals SpA; Treatment of Rett Syndrome

Day 60 discussion

Neurology

3.1.19. Immunoglobulin G4 - EMEA-002290-PIP01-17

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) / In combination with nivolumab for the treatment of malignant solid tumours in paediatric patients from 6 months to less than 18 years old

Day 60 discussion

Oncology

3.1.20. Diphtheria Toxin Interleukin-3 Fusion Protein - Orphan - EMEA-002244-PIP01-17

Stemline Therapeutics, Inc Treatment of all conditions included in the category of myeloid and lymphoid neoplasms expressing CD123

Day 60 discussion

Oncology

3.1.21. Molgramostim - Orphan - EMEA-002282-PIP01-17

Savara ApS; Treatment of Pulmonary Alveolar Proteinosis / Treatment of children from 2 to less than 18 years with secondary pulmonary alveolar proteinosis, Treatment of children from 2 to less than 18 years with autoimmune pulmonary alveolar proteinosis

Day 60 discussion

Pneumology - Allergology

3.1.22. Mavacamten - EMEA-002231-PIP01-17

Treatment of Hypertrophic Cardiomyopathy / Treatment of obstructive Hypertrophic Cardiomyopathy

Day 30 discussion

Cardiovascular Diseases

3.1.23. Trandolapril / verapamil - EMEA-002276-PIP01-17

Hypertension in adults

Day 30 discussion

Cardiovascular Diseases

3.1.24. Somapacitan - EMEA-001469-PIP02-17

Growth hormone deficiency, Short stature (ICD10 code: R6252)/ Treatment of paediatric patients with short stature born small for gestational age (SGA) with insufficient catch-up growth by age 2 to 4 years.

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.25. Relamorelin - EMEA-002323-PIP01-17

Diabetic Gastroparesis

Day 30 discussion

Gastroenterology-Hepatology

3.1.26. Brincidofovir - Orphan - EMEA-001904-PIP03-18

Chimerix UK Limited; Treatment of smallpox

Day 30 discussion

Infectious Diseases

3.1.27. Ibalizumab - EMEA-002311-PIP01-17

Treatment of human immunodeficiency virus (HIV-1) infection / Ibalizumab, a CD4 domain 2-directed HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of children and adolescents (aged 6 to less than 18 years) infected with HIV-1 resistant to at least 1 agent in 3 different classes.

Day 30 discussion

Infectious Diseases

3.1.28. Pretomanid - Orphan - EMEA-002115-PIP01-17

Global Alliance for TB Drug Development; Treatment of multi-drug-resistant tuberculosis

Day 30 discussion

Infectious Diseases

3.1.29. Rezafungin acetate - EMEA-002319-PIP01-17

Treatment of invasive candidiasis

Day 30 discussion

Infectious Diseases

3.1.30. Tedizolid phosphate - EMEA-001379-PIP03-17

Treatment of Gram-positive bacterial pneumonia

Day 30 discussion

Infectious Diseases

3.1.31. Andecaliximab - EMEA-002304-PIP01-17

Treatment of gastric adenocarcinoma

Day 30 discussion

Oncology

3.1.32. Brigatinib - EMEA-002296-PIP01-17

Inflammatory Myofibroblastic Tumors (IMT), Non-small cell lung cancer (NSCLC), Anaplastic large cell lymphoma (ALCL) / Treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)., Treatment of paediatric patients ≥2 years of age with ALK+ unresectable or recurrent IMT., Treatment in combination with standard chemotherapy in paediatric patients ≥2 years of age with newly diagnosed ALK+ ALCL at high risk for recurrence.

Day 30 discussion

Oncology

3.1.33. Botulinum Toxin Type A - EMEA-002149-PIP02-17

Cervical dystonia

Day 30 discussion

Other

3.1.34. Palovarotene - EMEA-001662-PIP03-17

Treatment of Multiple Osteochondromas (MO)

Day 30 discussion

Other

3.1.35. Meloxicam / Bupivacaine - EMEA-002246-PIP01-17

Acute Post Operative Pain

Day 30 discussion

Pain / Anaesthesiology

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Cobicistat / Darunavir - EMEA-C2-001280-PIP01-12-M01

Janssen-Cilag International NV; Treatment of HIV-1 infection

Day 30 discussion

Infectious Diseases

3.2.2. Ozanimod - EMEA-C3-001710-PIP02-14-M02

Celgene Europe Limited; Treatment of Multiple Sclerosis

Day 30 discussion

Neurology

3.2.3. Conestat Alfa - EMEA-C-000367-PIP01-08-M07

Pharming Group N.V.; Treatment of hereditary angioedema (HAE)

Day 30 discussion

Other

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Apixaban - EMEA-000183-PIP01-08-M06

Bristol-Myers Squibb / Pfizer EEIG; Prevention of arterial thromboembolism, Prevention of venous thromboembolism / Prevention of venous thromboembolism (VTE) in paediatric subjects (1 to < 18 years old) with a newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B cell), a functioning central venous access device (CVAD) and receiving asparaginase during chemotherapy induction., Prevention of TE in paediatric patients (birth to below 18 years old) with cardiac disease.

Day 30 discussion

Cardiovascular Diseases

3.3.2. Apixaban - EMEA-000183-PIP02-12-M02

Bristol-Myers Squibb / Pfizer EEIG; Treatment of venous thromboembolism

Day 30 discussion

Cardiovascular Diseases

3.3.3. Betrixaban - EMEA-001834-PIP02-16-M01

Portola Pharma UK Limited; Prevention of venous thromboembolism

Day 30 discussion

Cardiovascular Diseases

3.3.4. Apremilast - EMEA-000715-PIP03-11-M05

Celgene Europe Limited; Psoriasis in children

Day 30 discussion

Dermatology

3.3.5. Dupilumab - EMEA-001501-PIP01-13-M05

Regeneron Pharmaceuticals, Inc; Atopic dermatitis

Day 30 discussion

Dermatology

3.3.6. Vestronidase alfa - Orphan - EMEA-001540-PIP01-13-M03

Ultragenyx Germany GmbH; ICD-10: E76.2, Treatment of Mucopolysaccharidosis type VII (MPS VII)

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.7. Human Fibrinogen - EMEA-001208-PIP01-11-M04

Octapharma Pharmazeutika Produktionsges.m.b.H; Treatment of congenital fibrinogen deficiency, Treatment of acquired fibrinogen deficiency

Day 30 discussion

Haematology-Hemostaseology

3.3.8. Baricitinib - EMEA-001220-PIP01-11-M03

Eli Lilly and Company Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of juvenile idiopathic arthritis, Treatment of JIA-associated uveitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.9. Emapalumab - Orphan - EMEA-002031-PIP01-16-M01

Novimmune B.V; Treatment of Haemophagocytic Lymphohistiocytosis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.10. Ceftaroline fosamil - EMEA-000769-PIP01-09-M08

Pfizer Limited; Treatment of cSSTI (complicated skin and soft tissue infections) / Treatment of CAP (community-aquired pneumonia)

Day 30 discussion

Infectious Diseases

3.3.11. Ceftazidime / avibactam - EMEA-001313-PIP01-12-M07

Pfizer Limited; Treatment of bacterial infections / Treatment of complicated urinary tract infections / Treatment of hospital acquired pneumonia / Treatment of complicated intra-abdominal infections / Treatment of Gram-negative bacterial infections

Day 30 discussion

Infectious Diseases

3.3.12. Dasabuvir sodium monohydrate - EMEA-001439-PIP01-13-M02

Abbvie Ltd; Treatment of chronic hepatitis C / Treatment of children and adolescents from >= 3 years to less than 18 years of age with chronic HCV infection with compensated cirrhosis or without compensated cirrhosis in combination with ombitasvir, paritaprevir and ritonavir

Day 30 discussion

Infectious Diseases

3.3.13. EMEA-001975-PIP01-16-M01

Janssen-Cilag International NV; Treatment of influenza

Day 30 discussion

Infectious Diseases

3.3.14. Lamivudine (3TC) / Dolutegravir (DTG) - EMEA-001940-PIP01-16-M01

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.15. Ritonavir / paritaprevir / ombitasvir - EMEA-001440-PIP01-13-M02

Abbvie Ltd; Chronic Hepatitis C (HCV) infection / Treatment of children and adolescents from >= 3 years to < 18 years of age with chronic HCV infection with compensated cirrhosis or without compensated cirrhosis in combination with other medicinal products

Day 30 discussion

Infectious Diseases

3.3.16. Sofosbuvir - EMEA-001276-PIP01-12-M02

Gilead Sciences International Ltd.; Treatment of chronic Hepatitis C in adolescents and children 3 years of age and older

Day 30 discussion

Infectious Diseases

3.3.17. Tenofovir Alafenamide / Emtricitabine - EMEA-001577-PIP02-14-M03

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.18. Velpatasvir / Sofosbuvir - EMEA-001646-PIP01-14-M02

Gilead Sciences International Ltd.; Treatment of chronic Hepatitis C in adolescents and children 3 years of age and older

Day 30 discussion

Infectious Diseases

3.3.19. Fenfluramine hydrochloride - Orphan - EMEA-001990-PIP01-16-M01

Zogenix International Ltd; The adjunctive treatment of seizures in paediatric patients at least 1 year of age with Dravet syndrome

Day 30 discussion

Neurology

3.3.20. Perampanel - EMEA-000467-PIP01-08-M09

Eisai Europe Limited; Treatment of treatment-resistant epilepsies / Adjunctive therapy in patients with other paediatric epilepsies, Adjunctive therapy in patients with refractory partial onset seizures including secondarily generalised seizures

Day 30 discussion

Neurology

3.3.21. Spheroids of human autologous matrix-associated chondrocytes - EMEA-001264-PIP01-12-M02

CO.DON AG; Treatment of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee (International Cartilage Repair Society [ICRS] grade III or IV) with defect sizes up to 10 cm2

Day 30 discussion

Other

3.3.22. Formoterol fumarate dihydrate / Beclometasone dipropionate - EMEA-000548-PIP01-09-M08

Chiesi Farmaceutici S.p.A.; COPD, Asthma / Maintenance therapy of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists

Day 30 discussion

Pneumology - Allergology

3.3.23. Peanut flour - EMEA-001734-PIP01-14-M02

Aimmune Therapeutics Inc; Peanut Allergy / Peanut oral immunotherapy for the reduction in clinical reactivity to accidental exposure in peanut children and adults

Day 30 discussion

Pneumology - Allergology

3.3.24. Lurasidone hydrochloride - EMEA-001230-PIP01-11-M04

AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.p.A.; Schizophrenia

Day 30 discussion

Psychiatry

3.3.25. Etelcalcetide - EMEA-001554-PIP01-13-M02

Amgen Europe B.V.; Hyperparathyroid disorders / Hyperparathyroidism Secondary

Day 30 discussion

Uro-nephrology

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 29 May 2018 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

None

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. Recombinant human monoclonal antibody to GM-CSF - EMEA-02-2018

GlaxoSmithKline Trading Services Limited; All classes of medicinal products for treatment of primary and secondary osteoarthrosis/ Treatment of osteoarthritis in adult patients who are not adequately controlled by NSAIDs

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Note: EMEA-001882-PIP02-16 already agreed for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis).

6.1.2. Inhibitor of ADAMTS-5 - EMEA-03-2018

LES LABORATOIRES SERVIER; Treatment of primary and secondary osteoarthrosis/ Treatment of mild to moderate osteoarthritis of the knee and hip to reduce the degradation of cartilage

Summary of committee discussion:

Adoption of the outcome was postponed.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

None

8. Annual reports on deferrals

Note: The annual reports on deferrals to be noted by the members of the PDCO are flagged in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Change to timing of Scientific Committee Chair and Vice-Chair elections

Summary of committee discussion:

The Committee was updated on the change to timing of Scientific Committee Chair and Vice-Chair elections.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in February 2018 was presented to the PDCO members.

The members were also informed about 5 medicinal products, Alpivab, Amglidia, Mylotarg, Isentress and Kineret for which the CHMP adopted a positive opinion recommending a paediatric indication during their meeting in February 2018.

9.2.2. Committee for Medicinal Products for Human Use (CHMP)

Joint CHMP/PDCO session

Summary of committee discussion:

The committees discussed a product for multiple sclerosis.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.

9.3.3. Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP)

9.3.3.1. Draft Agenda of the PCWP/HCPWP joint meeting – 17-18 April 2018

Summary of committee discussion:

The document was tabled for information.

9.3.3.2. Draft PCWP/HCPWP Work Plan for 2018-2019

Summary of committee discussion:

The document was tabled for information.

9.3.4. Modelling and Simulation Working Group (MSWG)

Draft Paediatric Questions & Answers

MSWG member: Flora Musuamba Tshinanu and Kirstin Karlsson

Summary of committee discussion:

Experts form the MSWG presented over TC a draft Q&A on modelling and simulation and best approaches when dealing with paediatric studies. Comments are welcome from PDCO and should be sent within 2 weeks.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

9.4.2. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)

Request for PDCO advice (EMEA-000018-PIP01-07-M13)

PDCO member: Sabine Scherer

Summary of committee discussion:

The committee agreed to prepare responses to the various questions in writing. A small drafting group of PDCO members was established.

9.5. Cooperation with International Regulators

None

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

None

9.8. Planning and reporting

9.8.1. Strategic Review and Learning Meeting (SRLM) to be held in Vienna on 26-28 September 2018

PDCO member: Karl-Heinz Huemer

Summary of committee discussion:

The Committee was updated on the Strategic Review and Learning Meeting (SRLM) that will be held in Vienna on 26-28 September 2018.

10. Any other business

10.1. AOB topic

10.1.1. Reflections and action plan following the Multi-stakeholder workshop to further improve the implementation of the paediatric regulation (held on Tuesday 20 March 2018)

Summary of committee discussion:

The committee discussed the outcome of the EC/EMA multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation. The committee appreciated the open exchange with all main stakeholder groups. It was agreed that following the publication of a meeting report the EC/EMA in collaboration with the PDCO would develop a plan of concrete actions, which is planned to be published by mid-2018.

10.1.2. Involvement of young people at PDCO

Report on the conclusions of the discussion, which took place on 15 March 2018, on how to trigger involvement of young people in the PDCO.

PDCO members: Helena Fonseca, Francesca Rocchi, Dimitrios Athanasiou, Viviana Giannuzzi

Summary of committee discussion:

The committee was informed about a T-conference with representatives of the EMA Patient / Consumer WP, several PDCO members, and a representative of the European network of Young People Advisory Groups to elaborate practicalities on how to best implement involvement of young people into PDCO activities in line with EMA's "Principals on the involvement of young people".

EMA's Public Engagement department has a long experience with patient involvement in other committees and working parties and will provide organisational support.

Following discussions it was agreed to include into the Day 30 slides the discussion item: involvement of young people to ensure systematic consideration in all PIP-related PDCO discussions, starting already at next month meeting.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The group discussed planned activities and upcoming events in 2018.

11.1.2. Neonatology

Summary of committee discussion:

The group discussed about options of grading of adverse reactions in neonatology as part of their contribution to the International Neonatology Consortium and other current topics concerning neonates and related research.

11.1.3. Inventory

Summary of committee discussion:

The inventory group convened in the margins of the PDCO to progress on the discussion on the identification of unmet needs in children.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 20-23 March 2018 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	No participation in final deliberations and voting on:	EMEA-02-2018
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Adriana Andrić	Member	Croatia	No interests declared	
Suzana Mimica Matanovic	Alternate	Croatia	No interests declared	
Georgios Savva	Member	Cyprus	No interests declared	
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Peter Szitanyi	Alternate	Czech Republic	No interests declared	
Kirstine Moll Harboe	Member	Denmark	No interests declared	
Mona Ring Gatke	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Immanuel Barth	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Alessandro Jenkner	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Sigita Burokiene	Member	Lithuania	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Marek Migdal	Member	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Eva Agurell	Alternate	Sweden	No interests declared	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No interests declared	
Riccardo Riccardi	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Günter Karl-Heinz Auerswald	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Viviana Giannuzzi	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
Juliana Min	Expert - in person*	United Kingdom	No interests declared	
Shiva Ramroop	Expert - in person*	United Kingdom	No interests declared	
Catriona Baker	Expert - in person*	United Kingdom	No interests declared	
Eleni Gaki	Expert - in person*	United Kingdom	No interests declared	
Kirstin Karlsson	Expert - via telephone*	Sweden	No restrictions applicable to this meeting	
Flora Musuamba Tshinanu	Expert - via telephone*	Belgium	No interests declared	
Karolina Törneke	Expert - in person*	Sweden	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Friederike Lentz	Expert - via telephone*	BfarM	No interests declared	
Hans-Karl Heim	Expert - via telephone*	BfarM	No interests declared	
Karoline Buhre	Expert - via telephone*	BfarM	No restrictions applicable to this meeting	
Janet Koenig	Expert - in person*	BfarM	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived. For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website:
www.ema.europa.eu/